| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DOM.12223 |
| P698 | PubMed publication ID | 24719911 |
| P50 | author | Richard M Bergenstal | Q90594281 |
| P2093 | author name string | Y Qu | |
| J Rosenstock | |||
| M J Prince | |||
| S J Jacober | |||
| J M Beals | |||
| P2860 | cites work | Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus | Q34717929 |
| A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes | Q36334537 | ||
| Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study | Q36629558 | ||
| Does insulin detemir have a role in reducing risk of insulin-associated weight gain? | Q36772875 | ||
| Insulin-associated weight gain in diabetes--causes, effects and coping strategies | Q36966075 | ||
| Differences between long-acting insulins for the treatment of type 2 diabetes | Q37773993 | ||
| Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials | Q38898058 | ||
| Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group | Q45335458 | ||
| P433 | issue | 4 | |
| P921 | main subject | insulin glargine | Q417317 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 351-356 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. | |
| P478 | volume | 16 |
| Q30978373 | A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine |
| Q38620136 | Attenuated Suppression of Lipolysis Explains Increases in Triglyceride Secretion and Concentration with Basal Insulin Peglispro (BIL) Relative to Insulin Glargine Treatment in Patients with Type 1 Diabetes |
| Q51410348 | Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action. |
| Q52337945 | Characterisation of insulin analogues therapeutically available to patients. |
| Q41260941 | Glargine and degludec: Solution behaviour of higher dose synthetic insulins. |
| Q39023191 | How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes. |
| Q42491076 | In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog |
| Q46001828 | Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes. |
| Q36554243 | Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? |
| Q38778988 | Pursuit of a perfect insulin. |
| Q46082135 | Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes |
| Q22241148 | Role of insulin in the type 2 diabetes therapy: past, present and future |
Search more.